1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
GlycoNex, Inc.

GlycoNex, Inc.

TTPEX:4168
21.45
TWD
-0.30
(-1.38%)
-2.43EPS
2.88BMarket Cap
GlycoNex, Inc.
TPEX:4168
(Taipei Exchange)

Recent

price

21.45

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
0.41
1.97
1.18
0.55
0.1
0.09
- -
0.01
0.01
0.01
0.01
0.06
0.3
0.02
0.14
0.35
0.2
Revenue per Share
-2.1
0.49
0.22
-0.33
-0.53
-1.01
-1.27
-1.9
-4.15
-3.23
-1.82
-1.78
-2.2
-1.65
-2.12
-2.16
-2.43
Basic EPS, GAAP
-0.19
-2.02
-0.42
-2.12
-2.7
-9.91
-3.21
-2.53
-2.4
-2.37
-1.65
-1.52
-1.77
-1.92
-2.38
-1.59
-1.81
Free Cash Flow per Basic Share
- -
- -
0.02
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
4.99
7.99
15.14
30.41
29.02
27.69
25.57
24.15
20.05
16.99
15.73
13.88
13.46
11.77
9.65
8.73
7.56
Book Value per Share
4.83
7.75
14.73
30.1
27.97
26.79
24.83
23.55
19.84
16.92
15.73
13.88
13.46
11.77
9.61
8.68
7.52
Tangible Book Value per Share
25
40
54
65
77
76
76
76
76
77
90
97
100
108
108
109
111
Basic Weighted Avg Shares
10
80
63
36
8
7
- -
1
1
1
- -
5
30
3
15
38
22
Sales/Revenue/Turnover
-317.98
35.83
-3.39
-76.45
-765.02
-1,249.69
-43,610.88
-25,366.4
-34,727.97
-36,766.08
-47,476.5
-3,560.33
-793.22
-10,222.82
-1,674.14
-659.81
-1,342.98
Operating Margin (%)
5
7
8
9
12
30
36
53
57
55
47
40
40
31
34
35
36
Depreciation Expense
-53
20
12
-21
-41
-77
-97
-145
-317
-247
-163
-172
-220
-178
-230
-235
-270
Net Income, GAAP
- -
43.05
38.5
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-518.99
24.65
18.53
-60.05
-525.26
-1,107.54
-40,752.72
-22,805.68
-34,227.11
-33,682.15
-36,082.26
-3,150.56
-730.67
-7,016.6
-1,562.51
-621.29
-1,217.39
Profit Margin (%)
95
294
732
1,935
1,886
1,061
884
579
341
165
474
331
669
448
217
655
543
Working Capital
24
- -
- -
15
- -
- -
- -
- -
- -
- -
- -
- -
219
- -
- -
474
478
LT Debt
157
427
885
2,314
2,219
2,117
1,986
1,841
1,532
1,301
1,540
1,359
1,446
1,276
1,046
982
851
Total Equity
- -
5.29
-0.2
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
6.41
1.78
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-33.5
6.71
1.79
-1.34
-1.82
-3.56
-4.75
-7.55
-18.79
-17.45
-11.46
-11.9
-15.68
-13.11
-19.78
-23.19
-29.27
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1
- -
2
LT Borrowings
474
476
478
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
113
113
113
Market Capitalization
2,897
2,594
2,881

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
748
656
601
Cash, Cash Equivalents & STI
693
612
568
Accounts Receivable, Net
2
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
93
67
57
Payables & Accruals
- -
- -
- -
ST Debt
1
- -
2
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-6.82%
-8.24%
-6.13%
Free Cash Flow
-8.53%
5.68%
-32.8%
Net Income, GAAP
18.36%
9.15%
2.4%
Sales/Revenue/Turnover
216.32%
421.56%
157.54%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9
- -
2
3
15
2025
14
16
4
4
38
2026
12
2
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.67
-0.46
-0.41
-0.58
-2.12
2025
-0.41
-0.47
-0.55
-0.72
-2.16
2026
-0.67
-0.49
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
GlycoNex Incorporation is a biotechnology company primarily engaged in the development, manufacturing, and sales of innovative glycan-based products and solutions. Its core offerings include glycan reagents for research and diagnostics; glycan profiling and analysis services; bioactive glycan compounds; and custom glycan synthesis for pharmaceutical and life sciences applications. The company provides its products and services to academic research institutions, pharmaceutical companies, and diagnostic developers within Taiwan and internationally. Founded in 2005, GlycoNex is headquartered in Taipei, Taiwan. In the last 1-2 years, GlycoNex has made strategic expansions through partnerships with key pharmaceutical firms to accelerate its glycan biomarker discovery programs and has launched a new range of advanced glycan profiling kits aimed at enhancing precision diagnostics. GlycoNex has also enhanced its custom synthesis capabilities through recent investments in state-of-the-art manufacturing technologies, positioning itself as a leading glycomics solutions provider in the Asia-Pacific region. These developments reflect GlycoNex's commitment to innovation and its expansion into broader markets within the biotechnology and healthcare sectors.